TrialInvestigational new drugs2016

A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors.

Manik Amin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.